Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Obesity Setbacks For Amylin And Takeda

This article was originally published in The Pink Sheet Daily

Executive Summary

A Phase II trial for their Symlin-based combination therapy was halted after safety issues cropped up with patients from a previous study.
Advertisement

Related Content

Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option
Takeda, Sanford-Burnham Ink Obesity Discovery Deal To Explore Non-CNS Options
Amylin And Takeda Team Up In Obesity

Topics

Advertisement
UsernamePublicRestriction

Register

PS071964

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel